You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾和諾德指Hims & Hers違法賣仿製藥終止合作 後者股價盤前挫24%
丹麥藥廠諾和諾德(NVO.US)週一宣佈,因憂慮美國遠距醫療平臺Hims & Hers(HIMS.US)銷售及推廣違規仿製減肥藥Wegovy的行爲,決定終止與Hims & Hers的合作關係。消息拖累Hims & Hers股價於美股盤前大跌24%,諾和諾德亦跌7%。 諾和諾德今年4月開始透過多間遠距醫療公司包括Hims & Hers向患者處方Wegovy,以擴大該藥的普及性。不過,諾和諾德指控Hims & Hers以「個人化」治療作爲幌子,違法大量銷售仿製藥,甚至作出誤導性宣傳,其仿製藥活性成分部分從未獲美國FDA檢查,另有供應商曾被發現存在品質問題。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account